Expression of γ-H2AX in endometrial carcinomas: An immunohistochemical study with p53

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 206-211

  Brunner, Andreas H ^a   Hinterholzer, Susanne ^a   Riss, Paul ^a   Heinze, Georg ^b   Weiss, Katharina ^b   Brustmann, Hermann ^a  

^a Landesklinikum Thermenregion Moedling/Vienna ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

H2AX; Endometrial cancer; H2AX; Immunohistochemistry; p53

Indexed keywords

HISTONE GAMMA H2AX; HISTONE H2AX; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL CYCLE ARREST; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE FUNCTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE SECTION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952815581     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.037     Document Type: Article

References (31)

1. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5. (Pubitemid 30185164)
2. Jeggo PA, Loebrich M. DNA double-strand breaks: their cellular and clinical impact? Oncogene 2007;26:7717-9.
3. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedlniova OA, Solier S, et al. Gamma H2AX and cancer. Nat Rev Cancer 2008;12:957-67.
4. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 2008;22:305-9.
5. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair 2004;3:1227-35. (Pubitemid 38997966)
6. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352-5. (Pubitemid 351354863)
7. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedlniova OA, Solier S, et al. Gamma H2AX and cancer. Nat Rev Cancer 2008;12:957-67.
8. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23. (Pubitemid 39551659)
9. d'Adda di Fagagna F, Reaper PM, Clay-Farrace l, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescene. Nature 2003;426:194-8.
10. Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N, et al. The onset of p53- dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carciongenesis 2002;23:1025-32. (Pubitemid 34752959)
11. Bendet JL, Bender H, Jones III H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynecol Obstet 2000;70:209-62.
12. Nucci MR, Oliva E. Gynecologic pathology. Churchill Livingstone: Elsevier; 2009.
13. Brustmann H, Hinterholzer S, Brunner A. Expression of phosphorylated histone H2AX (γ-H2AX) in normal and neoplastic squamous epithelia of the uterine cervix: an immunohistochemical study with epidermal growth factor receptor. Int J Gynecol Pathol 2011;30:76-83.
14. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the results of treatment in gynaecological cancer. Int J Gynecol Obstet 2006;95:105-43.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70. (Pubitemid 40558993)
17. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13. (Pubitemid 40559004)
18. Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ. Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J Urol 2009;181:1387-92.
19. Warters RL, Adamson PJ, Pond CD, Leachman SA. Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol 2005;124:807-17. (Pubitemid 40489509)
20. Wasco MJ, Pu RT, Yu L, Su L, Ma L. Expression of γ-H2AX in melanocytic lesions. Hum Pathol 2008;39:1614-20.
21. Lane DP. Cancer. P53, guardian of the genom. Nature 1992;358:15-6.
22. Kohlberger P, Gitsch G, Loesch A, Tempfer C, Kaider A, Reinthaller A, et al. p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 1996;62: 213-7. (Pubitemid 26274802)
23. Kohler MF, Caney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175:1246-52.
24. Alkushi A, Köbel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29:343-50.
25. Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or Type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 2010;457:27-34.
26. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631-63.
27. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. Int J Gynecol Pathol 2005;24:184-92. (Pubitemid 40389543)
28. Nakamura AJ, Redon CE, Bonner WM. γ-H2AX: applications for the evaluation of telomerase-based cancer therapy. Cell Cycle 2010;17:3385-6.
29. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204. (Pubitemid 351301852)
30. Yang YC, Chao KS, Lin CP, Chen YY, Wang KL, Chen YJ. Oxaliplatin regulates DNA repair responding to ionizing radation and enhances radiosensitivity of human cervical cancer cells. Int J Gynecol Cancer 2009;19:782-6.
31. Park I, Park KK, Park JH, Chung WY. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett 2009;277:174-81.